Another anti-interleukin (IL)-17 inhibitor: is there an advantage of blocking IL-17A and IL-17F?
Bimekizumab is the fourth biologic inhibiting interleukin
(IL)-17 that has been approved for the treatment of plaquetype psoriasis in Europe.
Do we need it?
Preview
Rights
Use and reproduction:
Please note that individual components of the publication may be subject to other licensing or copyright conditions.
Cite
Citation style:
Could not load citation form.